Apogee Therapeutics initiates long-term safety study for APG777 in atopic dermatitis
Apogee Therapeutics is conducting a long-term safety and efficacy study for APG777 in patients with moderate-to-severe atopic dermatitis.
Company
Pharmaceutical intelligence for Apogee Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.